[go: up one dir, main page]

CR20220586A - Moléculas de fijación para el tratamiento de cáncer - Google Patents

Moléculas de fijación para el tratamiento de cáncer

Info

Publication number
CR20220586A
CR20220586A CR20220586A CR20220586A CR20220586A CR 20220586 A CR20220586 A CR 20220586A CR 20220586 A CR20220586 A CR 20220586A CR 20220586 A CR20220586 A CR 20220586A CR 20220586 A CR20220586 A CR 20220586A
Authority
CR
Costa Rica
Prior art keywords
cancer
treatment
binding molecules
same
fap
Prior art date
Application number
CR20220586A
Other languages
English (en)
Inventor
Pankaj Gupta
Abdallah Souabni
Inigo Tirapu
Joseph Ronald Tumang
Eric Borges
Justin M Scheer
Daniel Christopher Rowe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20220586A publication Critical patent/CR20220586A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a moléculas de fijación que se fijan específicamente a CD137 y FAP y su uso medicinal, composiciones farmacéuticas que las contienen y métodos para usarlas como agentes para el tratamiento y/o la prevención de cáncer.<br /> <br />  
CR20220586A 2020-05-19 2021-05-18 Moléculas de fijación para el tratamiento de cáncer CR20220586A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063026883P 2020-05-19 2020-05-19
US202063037241P 2020-06-10 2020-06-10
PCT/US2021/032990 WO2021236658A1 (en) 2020-05-19 2021-05-18 Binding molecules for the treatment of cancer

Publications (1)

Publication Number Publication Date
CR20220586A true CR20220586A (es) 2023-01-09

Family

ID=76502807

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220586A CR20220586A (es) 2020-05-19 2021-05-18 Moléculas de fijación para el tratamiento de cáncer

Country Status (18)

Country Link
US (2) US12146000B2 (es)
EP (1) EP4153316A1 (es)
JP (2) JP2023504675A (es)
KR (1) KR20230012559A (es)
CN (1) CN116249555A (es)
AU (1) AU2021276332A1 (es)
BR (1) BR112022021447A2 (es)
CA (1) CA3180665A1 (es)
CL (1) CL2022003213A1 (es)
CO (1) CO2022016754A2 (es)
CR (1) CR20220586A (es)
EC (1) ECSP22085835A (es)
IL (1) IL298287A (es)
MX (1) MX2022014538A (es)
PE (1) PE20230784A1 (es)
PH (1) PH12022553153A1 (es)
TW (1) TW202214303A (es)
WO (1) WO2021236658A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
WO2021252157A1 (en) * 2020-06-10 2021-12-16 Crystal Bioscience Inc. Anti-bdnf antibodies and methods of use thereof
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
CN119080935A (zh) * 2024-10-11 2024-12-06 上海市同仁医院 一种抗人SMIM45-107aa单克隆抗体及其用途

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3301833A1 (de) 1983-01-20 1984-07-26 Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig Verfahren zur simultanen synthese mehrerer oligonocleotide an fester phase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU2782292A (en) 1991-09-18 1993-04-27 Sloan-Kettering Institute For Cancer Research Activated stromal fibroblast-specific antibody, f19 and methods of using the same
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
ES2138662T3 (es) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2268340A1 (en) 1996-10-11 1998-04-23 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
CA2288992C (en) 1997-04-30 2012-06-12 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
WO2001068708A2 (en) 2000-03-17 2001-09-20 Boehringer Ingelheim Pharma Kg Human and humanized fap-alpha-specific antibodies
AU2001274809A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
CN1268394C (zh) 2001-01-17 2006-08-09 特鲁比昂药品公司 结合域－免疫球蛋白融合蛋白
PE20021080A1 (es) 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN117534755A (zh) 2005-05-09 2024-02-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
RU2425841C2 (ru) 2005-10-12 2011-08-10 МорфоСис АГ Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
ES2437327T3 (es) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Anticuerpos para el receptor PD-1 humano de muerte programada
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2709847C (en) 2008-01-07 2018-07-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2247305A4 (en) 2008-01-28 2012-11-14 Medimmune Ltd STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF
WO2009101611A1 (en) 2008-02-11 2009-08-20 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
US10265357B2 (en) 2008-10-08 2019-04-23 Viratherapeutics Gmbh Compositions, methods and uses for treating solid tumors using LCMV-GP-VSV pseudotype vectors
DE102008050860A1 (de) 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
JP5756802B2 (ja) 2009-08-13 2015-07-29 クリスタル バイオサイエンス インク．Ｃｒｙｓｔａｌ Ｂｉｏｓｃｉｅｎｃｅ Ｉｎｃ． 最小ｃｄｒを有する抗体を産生するトランスジェニック動物
CA2776037A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd Anti-fibroblast activation protein antibodies and methods and uses thereof
BR112012013736A2 (pt) 2009-12-07 2018-08-14 Univ Leland Stanford Junior processo para intesificação de terapia com anticorpos antitumor
MY177065A (en) 2010-09-09 2020-09-03 Pfizer 4-1bb binding molecules
WO2012069655A2 (en) 2010-11-26 2012-05-31 Molecular Partners Ag Improved n-terminal capping modules for designed ankyrin repeat proteins
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
US9494926B2 (en) 2011-10-05 2016-11-15 Opteon Corporation Methods and apparatus employing an action engine for monitoring and/or controlling dynamic environments
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3102604B1 (en) 2014-02-04 2020-01-15 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
US9494125B2 (en) 2014-06-13 2016-11-15 Innova Electronics, Inc. System and method of ignition coil testing
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
WO2016109546A2 (en) 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
JP2018510613A (ja) 2015-01-09 2018-04-19 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）抗体およびその派生使用
US10259881B2 (en) 2015-02-22 2019-04-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
BR112017024770A2 (pt) 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
RU2761115C1 (ru) 2015-10-02 2021-12-06 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, специфические в отношении костимуляторного tnf-рецептора
CR20180171A (es) 2015-10-07 2018-05-03 Hoffmann La Roche Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
JP6384461B2 (ja) 2015-12-03 2018-09-05 株式会社デンソー リリーフ弁装置、及び、それを用いる高圧ポンプ
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
DE102016000353A1 (de) 2016-01-14 2017-07-20 Liebherr-Components Biberach Gmbh Kran-, Baumaschinen- oder Flurförderzeug-Simulator
EP3408294A1 (en) 2016-01-25 2018-12-05 Pfizer Inc. Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
WO2017178653A2 (en) 2016-04-14 2017-10-19 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
MX2018012897A (es) 2016-04-22 2019-01-17 Alligator Bioscience Ab Nuevos polipeptidos biespecificos contra cd137.
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
CA3025345A1 (en) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
ES2995596T3 (en) 2016-06-14 2025-02-10 Xencor Inc Bispecific checkpoint inhibitor antibodies
US10360201B2 (en) 2016-07-11 2019-07-23 Investcloud Inc Data exchange common interface configuration
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
EP3515936A1 (en) 2016-09-23 2019-07-31 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
JP6997778B2 (ja) 2016-11-10 2022-02-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 距離に基づく腫瘍分類
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
EP3360898A1 (en) * 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
MA47200A (fr) 2017-01-03 2019-11-13 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb
SG11201903021WA (en) 2017-01-06 2019-05-30 Eutilex Co Ltd Anti-human 4-1 bb antibodies and use thereof
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
JP7256744B2 (ja) 2017-01-20 2023-04-12 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１３７＋細胞の枯渇のための組成物および方法
US10123435B2 (en) 2017-02-02 2018-11-06 Lg Electronics Inc. Display control module and display device including the same
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
EP3652209A2 (en) 2017-07-11 2020-05-20 Compass Therapeutics LLC Agonist antibodies that bind human cd137 and uses thereof
US10961318B2 (en) 2017-07-26 2021-03-30 Forty Seven, Inc. Anti-SIRP-α antibodies and related methods
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
MA50352A (fr) 2017-10-10 2020-08-19 Numab Therapeutics AG Anticorps multispécifiques
JP7438939B2 (ja) 2017-10-10 2024-02-27 ヌマブ セラピューティクス アクチェンゲゼルシャフト Ｃｄ１３７を標的とする抗体とその利用方法
CN111182944B (zh) * 2017-11-01 2022-11-22 豪夫迈·罗氏有限公司 双特异性2+1 Contorsbody
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
US20210015866A1 (en) 2018-03-23 2021-01-21 La Jolla Institute For Allergy And Immunology Tissue resident memory cell profiles, and uses thereof
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
EP3856787A4 (en) 2018-09-27 2022-06-29 Celgene Corporation SIRPalpha BINDING PROTEINS AND METHODS OF USE THEREOF
KR20250067177A (ko) 2019-01-25 2025-05-14 베링거 인겔하임 인터내셔날 게엠베하 Ccl21을 인코딩하는 재조합 랍도바이러스
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子

Also Published As

Publication number Publication date
CN116249555A (zh) 2023-06-09
CL2022003213A1 (es) 2023-06-30
US12146000B2 (en) 2024-11-19
TW202214303A (zh) 2022-04-16
KR20230012559A (ko) 2023-01-26
MX2022014538A (es) 2022-12-15
PE20230784A1 (es) 2023-05-11
IL298287A (en) 2023-01-01
CO2022016754A2 (es) 2022-11-29
PH12022553153A1 (en) 2024-02-26
CA3180665A1 (en) 2021-11-25
WO2021236658A1 (en) 2021-11-25
JP2024054284A (ja) 2024-04-16
ECSP22085835A (es) 2022-12-30
JP2023504675A (ja) 2023-02-06
BR112022021447A2 (pt) 2022-12-13
AU2021276332A1 (en) 2022-11-17
US20210363273A1 (en) 2021-11-25
EP4153316A1 (en) 2023-03-29
US20250136720A1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
PH12022553153A1 (en) Binding molecules for the treatment of cancer
PH12017501583A1 (en) Novel proteins specific for cd137
WO2019032662A8 (en) Clec9a binding agents and use thereof
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
MX2021005350A (es) Compuestos de piridazinona y usos de los mismos.
MX2019002474A (es) Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
EA201991480A1 (ru) Биспецифические молекулы, связывающиеся со связанным с анти-фно вызывающим апоптоз рецептором 2 лиганда и анти-кадгерином 17 для лечения рака
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
MX2019008434A (es) Muteínas de lipocalina con afinidad de unión por lag-3.
PH12022552323A1 (en) Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
MX2022015490A (es) Imagen y terapia dirigida a granzima b.
PH12020500666A1 (en) Pladienolide compounds and their use
MX2025008431A (es) Proteinas de fusion fc de il-12
MY209035A (en) Tricyclic compounds and their use
MX2021009189A (es) Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer.
MX2020012805A (es) Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.
WO2022084355A3 (en) Agonistic trkb binding molecules for the treatment of eye diseases